Beijing Tiantan Biological Products Corp Ltd
600161
Company Profile
Business description
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others.
Contact
No. 2, Shuangqiao Road
Chaoyang District
Beijing100024
CHNT: +86 1065434018
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5,205
Stocks News & Analysis
stocks
The 10 best US companies to invest in now
The stocks of these high-quality companies look cheap today.
stocks
Surge in combat drones drives upgrade for ASX share
Drone demand powers growth but investor optimism is overdone.
stocks
Meta: Meta launches enterprise offering to open up another way to monetize AI investments
The market’s negative reaction to the announcement signals that investors, much like us, are not super excited about Meta’s prospects in the enterprise market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,886.10 | 31.40 | 0.35% |
| CAC 40 | 7,897.19 | 61.88 | 0.79% |
| DAX 40 | 25,231.20 | 291.85 | 1.17% |
| Dow JONES (US) | 51,176.96 | 250.40 | 0.49% |
| FTSE 100 | 10,461.95 | 33.68 | 0.32% |
| HKSE | 23,929.35 | 42.94 | -0.18% |
| NASDAQ | 27,190.86 | 319.27 | 1.19% |
| Nikkei 225 | 69,993.34 | 1,683.88 | 2.47% |
| NZX 50 Index | 13,661.08 | 19.41 | -0.14% |
| S&P 500 | 7,722.72 | 56.27 | 0.73% |
| S&P/ASX 200 | 8,712.10 | 30.00 | 0.35% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |